Search Results

Celtarys Research expands its assay tools with CELT-419 for D3 receptor studies, and Dr. Maria Majellaro shares her journey to founding Celtarys in "From Lab to Leadership". Subscribe to The Kenakin Brief Fluorescent Probe CELT-419 Powers D3R Binding Assays Across Platforms   Celtarys GPCR Partner Tools The Story Behind Celtarys – From Chemistry to Company   How does a medicinal chemist Maria Majellaro’s path from lab research to co-founding Celtarys, as told in her recent Dr.

This collaboration aims to amplify the visibility and adoption of Celtarys’ cutting-edge fluorescent Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology “This partnership will help accelerate the adoption of our chemical tools and foster collaborations that Maria Majellaro , CSO of Celtarys. “Working with Dr. About Celtarys Research Celtarys Research is a biotech company based in Spain that specializes in the

At Celtarys, we focus on developing fluorescent tools that keep minimal background signal even without Celtarys’ protocol section includes detailed protocols for diverse applications and fluorescent ligands

This was a very enriching experience for Maria, not only did she have a chance to share Celtarys’ technology

Maria Majellaro Now, she leads a team of talented chemists at Celtarys, developing fluorescent ligands GPCR x Celtarys partnership , she’s extending those insights to researchers worldwide. 👉 Explore Celtarys ’ tools and partnership with Dr.

This is Lucía from the Celtarys Research chemistry team.  For our very first post in this ecosystem, we wanted to highlight a huge part of our work at Celtarys to be removed completely, otherwise it can quelate biomolecules or induce cell toxicity. [ 5]     At Celtarys

Celtarys Research Joins Dr. GPCR – Precision Tools for GPCR Assays Dr. GPCR and Celtarys Research have teamed up. This partnership aims to bring advanced chemical probe strategies to the forefront. Explore the partnership Multiplexing GPCR Discovery - Sakmar Lab’s Toolkit Goes Public The latest podcast

If you’ve read our previous post, you probably know what CELT-335 is and its high affinity for the cannabinoid 1 receptor (CB1R). During that project we tested its validity as a fluorescent probe for Tag-lite® assays, where we used a set of 7 cannabinoid ligands (both natural and synthetic) to validate and optimize the assay. Because Tag-lite® is based on FRET, we have collaborated with BMG Labtech to develop an application note where CELT-335 is used to differentiate binding of THC derivatives to CB1R. Introduction Cannabinoid receptors are GPCRs, and two main types exist, CB1R and CB2R. CB1R are mainly found in the central nervous system (CNS) and the brain. They regulate mood, memory, appetite and motor function. CB2R are located primarily in the immune system and peripheral tissues, where they modulate inflammation and immune response. Cannabinoids have the potential to treat a variety of diseases, including neurological and metabolic conditions. This interest has been driving efforts to understand their pharmacology since the 1980s. It has been proven that when different ligands bind to the receptors the effects are different depending on which signaling pathway is activated, which is called ‘bias signaling’. The bias depends on the agonist’s structure as well as the state of the cannabinoid receptor (whether it’s monomeric or heteomeric). Here, the PHERAstart FSX microplate reader was used to differentiate binding of natural cannabinoids to CB1R based on TR-FRET assays. In this case, Terbium is used as donor and CELT-335 fluorescent ligand is used as acceptor. Figure 1.Combinational optical spectra of terbium (Tb) and CELT-335: The terbium (donor) emission spectrum overlaps with the CELT-335 (acceptor) excitation spectrum. CELT-335 was successfully used in assays to determine the pharmacological properties of Δ9-tetrahydrocannabinol (Δ9-THC), Δ9-tetrahydrocannabinolic acid (Δ9-THCA) and Δ9-tetrahydrocannabivarin (Δ9-THCV) when binding to CB1R. Assay Principle CELT-335 is a fluorescently labelled full agonist, which binds to the orthosteric site of the human CBRs. It bears a hydrophilic fluorophore compatible with the terbium donor in TR-FRET assays. It binds to the receptor, which is labelled with Tb. When this happens the proximity between donor and acceptor is sufficient for a transmission of energy to occur between the Tb and fluorophore, which will emit at 665nm. Figure 2.Assay Principle: TR-FRET assay using CELT-335, a dual (CB1/CB2) fluorescent ligand that serves as a TR-FERT acceptor. Results and Discussion The TR-FRET assay performed in living HEK-293 T cells expressing CB1R using CELT-335 as acceptor provides a sensitive and robust measurement for competition binding experiments. The curves were obtained using 100nM of probe and increasing concentrations of Δ9-THC, Δ9-THCA and Δ9-THCV (0 – 10 μM). Competition was similar for Δ9-THC and Δ9-THCV, but considerably lower for Δ9-THCA. The data obtained is comparable to those reported in radioligand binding assays (Table 1). Figure 3.TR-FRET competition assay between CELT-335 (TR-FRET acceptor) and Δ9-THC, Δ9-THCA and                     Δ9-THCV.Data represent the mean ± SEM (n = 5 in triplicates) Table 1. Comparison of binding affi nities using radioligand binding or TR-FRET assays. Radioligand binding data are from [2,3]. Conclusion CELT-335 is a functional TR-FRET acceptor which can be coupled with Tb as donor. It has shown high affinity for the CB1R, and the binding affinity values obtained for natural cannabinoids and their derivatives are comparable values to those reported in literature [2,3]. These assays probide a reliable way to measure binding affinities for CB1R in live cells and the PHERAstar FSX is the ideal microplate reader for characterizing the GPCR-ligand interactions. If you want to check out the Materials and Methods section as well as the application note, here is the link to our website ! If you are interested in our ligands or technology, feel free to contact me anytime. References 1. Raïch I et al. , Similarities and differences upon binding of naturally occurring Δ9-tetrahydrocannabinolderivatives to cannabinoid CB1 and CB2 receptors, Pharmacological Research (2021) 174: 105970, doi: 10.1016/j.phrs.2021.105970 2. Zagzoog A et al ., In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis   sativa , Scientifi c Reports (2020) 10(1):20405. doi: 10.1038/s41598-020-77175-y 3. Palomares B et al. , Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors, British Journal of Pharmacology (2020) 177(17): 4034-4054. doi: 10.1111/bph.15155.

Hello GPCR Trailblazers, This week, we’re spotlighting Celtarys Research, our newest partner, featured Explore Terry's Corner From Chemistry Lab to GPCR Partner – New Podcast with Celtarys Dr. Maria Majellaro of Celtarys shares how her team translates medicinal chemistry into practical GPCR assay tools—and how their new partnership with Dr. Introducing Celtarys - Probe Development via Conjugation Strategies   Celtarys Research's first article

innovative target identification through multiparametric approaches, announce today the signing of a partnership

August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a treatment they hope will bring immunotherapy benefits to new cancer types. Jonah Comstock delves into what makes this team-up tick. Cancer Research UK, a charity dedicated to funding lifesaving oncology research, spent £388 million on cancer research last fiscal year. Much of that funding is distributed to support third party research, but the group also does its own research into promising therapy areas, working with partners who have a good idea but don’t have all the necessary tools to drive it forward." Read more at the source #DrGPCR #GPCR #IndustryNews

Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships

Maria Majellaro makes it clear that Celtarys isn’t just a ligand provider. And that mindset is precisely what makes their new partnership with Dr. GPCR so powerful. Maria Majellaro Celtarys specializes in the custom development of fluorescent ligands  using a modular Whether supporting CROs, academic labs, or pharma teams, Celtarys engages deeply with collaborators to GPCR ecosystem , Celtarys is opening up that model to the broader research community. The goal?

GPCR Podcast, she shares how her background in medicinal chemistry paved the way to co-founding Celtarys Celtarys was born out of necessity.   Celtarys Research, now partnering with Dr. . 👉 Learn more about Celtarys’ science-driven solutions on their company page . _______________ Keyword

Plus, Celtarys explores ligand selection for better assays, and co-founder Dr. Radioligands – Assay Smarter Celtarys explores how fluorescent ligands enable safer, high-throughput Upgrade Your Screening Strategy Leadership in Ligand Design  – The Celtarys Origin Story   In  this founder Maria Majellaro reveals how Celtarys evolved from a vision into a company solving real-world assay problems

Yamina’s Corner opens for strategic consulting, and our partner Celtarys unveils a robust TR-FRET assay Visit Yamina’s Corner Now CELT-335 - Celtarys Validates New Assay for CB1/CB2 Screening Dr. GPCR partner Celtarys Research has validated a TR-FRET assay for cannabinoid receptor ligands using their

We have carried out MARTINI coarse-grained molecular dynamics simulations of SMO in POPC and in ciliary models, respectively, to study the interactions of SMO with cholesterol and other lipid molecules in the ciliary

#ai #biotech #systemsbiology #drugdiscovery #gpcr #deeptech #orphandrugs #pharma #partnerships #AI4drugdiscovery

pairs Expanding Time-Resolved Fluorescence Applications in Drug Discovery Beyond Traditional Methods At Celtarys Celtarys enhances the power of HTRF and other FRET-based technologies by providing high-performance By combining deep expertise in GPCR biology with advanced fluorescence chemistry, Celtarys custom-developed

GPCR: A Mission-Aligned Partnership That Advances the Field At Dr. critical moments that changed everything. 👉 Discover the pHSense™ Reagents + Listen to the podcast ➤ Celtarys A new contributor article from our friends at Celtrays Research outlines how dual-labeled fluorescent

PerkinElmer High Content Analysis System Operetta CLS used by a Celtarys Research coworker. At Celtarys, our GPCR fluorescent ligands are designed with a variety of photophysical properties to

This year, we focused on building for sustainability  — strengthening operations, expanding partnerships Strategic Partnerships with Purpose Dr. Our strategic partnerships  reflect that mission. Our partnerships with Celtarys Research  and Revvity are great examples — uniting innovation and application Terry’s Pharmacology Corner → TerryKenakin.com 📧 Connect with us →   Hello@DrGPCR.org 📧  Learn About Partnerships

🔹 Innovate faster → Celtarys’s newest GPCR tools Explore new screening tools purpose-built for

The future of discovery will belong to scientists who know how to build the right partnerships and stay That mindset shaped his partnership with JB, the chemist who would eventually help his lab visualize This is where GPCR science is heading: toward deeper integration, shared tools, and partnerships that This conversation is part of a three episode series produced in collaboration with our partners at Celtarys

That partnership eventually produced fluorescent GPCR tools  that allow researchers to visualize GPCR This conversation is part of a three episode series produced in collaboration with our partners at Celtarys

What followed — a trip to London, confocal imaging marathons, and a partnership built on trust and curiosity It was the start of a scientific partnership with the potential to shift how GPCRs could be visualized Collaboration as the Driver Behind Today’s GPCR Imaging Breakthroughs Behind the technical success lies a partnership This conversation is part of a three episode series produced in collaboration with our partners at Celtarys

This conversation is part of a three episode series produced in collaboration with our partners at Celtarys

reproducible high-throughput assays  A smoother transition from screening to mechanistic studies At Celtarys At Celtarys, we remain committed to enabling this transition and supporting researchers as they design

This conversation is part of a three episode series produced in collaboration with our partners at Celtarys

This feature from Celtarys Research outlines how to structure an HCS workflow that avoids batch effects